Lymphoma | Norton Healthcare

Indication: Lymphoma

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with
Rituximab Versus Immunochemotherapy in Patients with Relapsed or
Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: ADC Therapeutics SA

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.